Neural Precursor Cells for Delivery of Replication-Conditional HSV-1 Vectors to Intracerebral Gliomas

Molecular Therapy

Volumn 1, Issue 4, 2000, Pages 347-357

  Herrlinger, Ulrich ^a,c   Woiciechowski, Christian ^b,d   Sena Esteves, Miguel ^a   Aboody, Karen S ^b   Jacobs, Andreas H ^a,e   Rainov, Nikolai G ^b,f   Snyder, Evan Y ^b   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

DNA replication; Gene therapy; Glioma; HSV 1; Migration; Neural precursor cells; Virus vector

Indexed keywords

GANCICLOVIR; MIMOSINE; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; TRANSACTIVATOR PROTEIN;

ANIMAL; ARTICLE; BRAIN TUMOR; CELL MOTION; CYTOLOGY; DRUG EFFECT; GENE THERAPY; GENE VECTOR; GENETICS; GLIOMA; HERPES SIMPLEX VIRUS 1; METHODOLOGY; MOUSE; MUTATION; NERVE CELL; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; STEM CELL; VIROLOGY; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; CELL MOVEMENT; GANCICLOVIR; GENE THERAPY; GENES, VIRAL; GENETIC VECTORS; GLIOMA; HERPES SIMPLEX VIRUS PROTEIN VMW65; HERPESVIRUS 1, HUMAN; MICE; MICE, NUDE; MIMOSINE; MUTATION; NEURONS; RIBONUCLEOTIDE REDUCTASES; STEM CELLS; THYMIDINE KINASE; VIRUS REPLICATION;

EID: 0034169521     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0046     Document Type: Article

References (65)

1. Hunter W., Rabkin S., Martuza R. Brain tumor therapy using genetically engineered replication-competent virus. Kaplitt M. G., Lowey A. D. Viral Vectors. 1995;259-274 Academic Press, New York.
2. Breakefield X. O., Kramm C. M., Chiocca E. A., Pechan P. A. Herpes simplex virus vectors for tumor therapy. Sobol R. E., Scanlon K. J. The Internet Book of Gene Therapy: Cancer Gene Therapeutics. 1995;41-56 Appleton and Lange, Stamford.
3. Herrlinger, U, Jacobs, A, and, Breakefield, X. O. in press, HSV-1 vectors for therapy of experimental CNS tumors. In, Methods in Molecular Medicine, Gene Therapy Protocols, (, P. Robbins, Ed.), Humana Press, Totowa, NJ.
4. Glorioso J. C., Bender M. A., Goins W. F., Fink D. J., DeLuca N. Herpes simplex virus as a gene-delivery vector for the central nervous system. Viral Vectors. 1995;Academic Press, New York. p. 1-23.
5. Breakefield X. O., Pechan P., Johnston K., Jacoby D. Herpes virus vectors. Quesenberry P. J., Stein G. J., Forget B., Weissman S. Stem Cell Biology and Gene Therapy. 1998;201-233 Wiley-Liss, New York.
6. Rampling R., Papanastassiou V., Cruickshank G., Brown M., Hadley D., Petty R., McKie E. Phase I study of therapeutic HSV 1716 in recurrent glioma. J. Neuro-Oncol. 39:1998;158.
7. Martuza R. L. Herpesvirus targeting of glioblastomas. 1st Annual Meeting ASGT. 1998.
8. Martuza R. L., Malick A., Markert J. M., Ruffner K. L., Coen D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 252:1991;854-856.
9. Kaplitt M. G., Tjuvajev J. G., Leib D. A., Berk J., Pettigrew D. K., Posner J. B., Pfaff D. W., Rabkin S. D., Blasberg R. G. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neuro-Oncol. 19:1994;137-147.
10. Goldstein D. J., Weller S. K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62:1988;196-205.
11. Boviatsis E. J., Chase M., Wei M., Tamiya T., Hurford R. K., Kowall N. W., Tepper R. I., Breakefield X. O., Chiocca E. A. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus (HSV), and retrovirus vectors. Hum. Gene Ther. 5:1994;183-191.
12. Pyles R. B., Thompson R. L. Evidence that herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J. Virol. 68:1994;4963-4972.
13. Mineta T., Rabkin S. D., Yazaki T., Hunter W. D., Martuza R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1:1995;938-943.
14. Pyles R. B., Warnick R. E., Chalk C. L., Szanti B. E., Parysek L. M. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8:1997;533-544.
15. Kramm C. M., Chase M., Herrlinger U., Jacobs A., Pechan P., Rainov N. G., Sena-Esteves M., Aghi M., Barnett F. H., Chiocca E. A., Breakefield X. O. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8:1997;2057-2068.
16. Coukos G., Makrigiannakis A., Kang E. H., Caparelli D., Benjamin I., Kaiser L. R., Rubin S. C., Albelda S. M., Molnar-Kimber K. L. Use of carrier cells to delivery a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res. 5:1999;1523-1537.
17. Kleihues P., Burger P. C., Plate K. H., Ohgaki H., Cavenee W. K. Glioblastoma. Kleihues P., Cavenee W. K. Pathology and Genetics of Tumors in the Nervous System. 1997;16-24 International Agency for Research on Cancer, Lyon.
18. Short M. P., Choi B. C., Lee J. K., Malick A., Breakefield X. O., Martuza R. L. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27:1990;427-439.
19. Culver K. W., Ram Z., Walbridge S., Hirouki K., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
20. Kramm C. M., Sena-Esteves M., Barnett F., Rainov N., Schuback D., Yu J., Pechan P., Paulus W., Chiocca E. A., Breakefield X. O. Gene therapy for brain tumors. Brain Pathol. 5:1995;345-381.
21. Tamura M., Shimizu K., Yamada M., Miyao Y., Hayakawa T., Ikenaka K. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Hum. Gene Ther. 8:1997;381-391.
22. Lal B., Indurti R. R., Couraud P. O., Goldstein G. W., Laterra J. Endothelial cell implantation and survival within experimental gliomas. Proc. Natl. Acad. Sci. USA. 91:1994;9695-9699.
23. Ojeifo J. O., Reza F., Paik S., Maciag T., Zwiebel J. A. Angiogenesis-directed implantation of genetically modified endothelial cells in mice. Cancer Res. 55:1995;2240-2244.
24. Tamura M., Ikenaka K., Tamura K., Yoshimatsu T., Miyao Y., Kishima H., Mabuchi E., Shimizu K. Transduction of glioma cells using a high-titer retroviral vector system and their subsequent migration in brain tumors. Gene Ther. 5:1998;1698-1704.
25. Snyder E. Y., Macklis J. D. Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy of some neurodegenerative conditions. Clin. Neurosci. 3:1996;310-316.
26. Snyder E. Y., Deitcher D. L., Walsh C., Arnold-Aldea S., Hartwieg E. A., Cepko C. L. Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell. 68:1992;33-51.
27. Jamieson D. R., Robinson L. H., Daksis J. I., Nicholl M. J., Preston C. M. Quiescent viral genomes in human fibroblasts after infection with herpes simplex virus type 1 Vmw65 mutants. J. Gen. Virol. 76:1995;1417-1431.
28. Hylin J. W. Toxic peptides and amino acids in foods and feeds. J. Agr. Food Chem. 17:1969;492-496.
29. Mosca P. J., Kijkwel P. A., Hamlin J. L. The plant amino acid mimosine may inhibit initiation of replication at origins of replication in Chinese hamster cells. Mol. Cell Biol. 12:1992;4375-4383.
30. Dai Y., Gold B., Vishwanatha J. K., Rhode S. L. Mimosine inhibits viral DNA synthesis through ribonucleotide reductase. Virology. 205:1994;210-216.
31. Faulds D., Heel R. C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 39:1990;597-638.
32. Wigdahl B., Smith C. A., Traglia H. M., Rapp F. Herpes simplex virus latency in isolated human neurons. Proc. Natl. Acad. Sci. USA. 81:1984;6217-6221.
33. Wilcox C. L., Johnson E. M. Nerve growth factor deprivation results in the reactivation of latent herpes simplex virus in vitro. J. Virol. 61:1987;2311-2315.
34. Cook S. D., Paveloff M. J., Doucet J. J., Cottingham A. J., Sedaraati F., Hill J. M. Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants. Invest. Ophthalmol. Vis. Sci. 32:1991;1558-1561.
35. Halford W. P., Gebhardt B. M., Carr D. J. J. Mechanisms of herpes simplex virus type 1 reactivation. J. Virol. 70:1996;5051-5060.
36. Hardwicke M. A., Schaffer P. A. Differential effects of nerve growth factor and dexamethasone on herpes simplex virus type 1 oriL and oriS-dependent DNA replication in PC12 cells. J. Virol. 71:1997;3580-3587.
37. Kramer M. F., Coen D. M. Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J. Virol. 69:1995;1389-1399.
38. Zhu X., Chen J., Young C. S. H., Silverstein S. Reactivation of latent herpes simplex virus by adenovirus recombinants encoding mutant IE-0 gene products. J. Virol. 64:1990;4489-4498.
39. Cai W., Astor T. L., Liptak L. M., Cho C., Coen D. M., Schaffer P. A. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during active infection and reactivation from latency. J. Virol. 67:1993;7501-7512.
40. Sears A. E., Hukkanen V., Labow M. A., Levine A. J., Roizman B. Expression of the herpes simplex virus 1 alpha transinducing factor (VP16) does not induce reactivation of latent virus or prevent the establishment of latency in mice. J. Virol. 65:1991;2929-2935.
41. Jacobson G. J., Ruffner K. L., Kosz-Vnenchak M., Hwang C. B. C., Wobbe K. K., Knipe D. M., Coen D. M. Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia. J. Virol. 67:1993;6903-6908.
42. Wilcox C. L., Crnic L. S., Pizer L. I. Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant. Virology. 186:1992;348-352.
43. Chang J. Y., Johnson E. M., Olivo P. D. A gene delivery/recall system for neurons which utilizes ribonucleotide reductase-negative herpes simplex viruses. Virology. 185:1991;437-440.
44. Chase M., Chung R. Y., Chiocca E. A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16:1998;444-448.
45. Roizman B., Spear P. G. Preparation of herpes simplex virus of high titer. J. Virol. 2:1968;83-84.
46. Kruse C. A., Molleston M., Parks E. P., Schiltz P. M., Kleinschmidt-DeMasters B. K., Hickey W. F. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: A comparison to 9L gliosarcoma. J. Neuro-Oncol. 22:1994;191-200.
47. Byre G. W., Ruddle F. H. Multiplex gene regulation: A two-tiered approach to transgene regulation in transgenic mice. Proc. Natl. Acad. Sci. USA. 86:1989;5473-5477.
48. Bergold P. J., Casaccia-Bonnefil P., Zeng X. L., Federoff H. J. Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor. Proc. Natl. Acad. Sci. USA. 90:1993;6165-6169.
49. Geller A. I., Breakefield X. O. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science. 241:1988;1667-1669.
50. Fraefel C., Song S., Lim F., Lang P., Yu L., Wang Y., Wild P., Geller A. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70:1996;7190-7197.
51. Cunningham C., Davison A. J. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology. 197:1993;116-124.
52. Smith I. L., Hardwicke M., Sandri-Goldin R. M. Evidence that the herpes simplex virus immediate protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology. 186:1992;74-86.
53. Turner D. L., Snyder E. Y., Cepko C. L. Lineage-independent determination of cell type in the embryonic mouse retina. Neuron. 4:1990;833-845.
54. Lynch W. P., Sharpe A. H., Snyder E. Y. Neural stem cells as engraftable packaging lines optimize viral vector-mediated gene delivery to the CNS: Evidence from studying retroviral env-related neurodegeneration. J. Virol. 73:1999;6841-6851.
55. Sawtell N. M. Comprehensive quantification of herpes simplex virus latency at the single-cell level. J. Virol. 71:1997;5423-5431.
56. Nichol P. F., Chang J. Y., Johnson E. M. J., Olivo P. D. Herpes simplex virus gene expression in neurons: Viral DNA synthesis is a critical regulatory event in the branch point between the lytic and latent pathways. J. Virol. 70:1996;5476-5486.
57. Kosz-Vnenchak M., Coen D. M., Knipe D. M. Restricted expression of herpes simplex virus lytic genes during the establishment of latent infection by thymidine kinase-negative mutant viruses. J. Virol. 64:1990;5396-5402.
58. Leist T. P., Sandri-Goldin R. M., Stevens J. G. Latent infections in spinal ganglia with thymidine kinase-deficient herpes simplex virus. J. Virol. 63:1989;4976-4978.
59. Tal-Singer R., Lasner T. M., Podrzucki W., Skokotas A., Leary J. J., Berger S. L., Fraser N. Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures. J. Virol. 71:1997;5268-5276.
60. Gossen M., Bujard H. Anhydrotetracycline, a novel effector for tetracycline controlled gene expression systems in eukaryotic cells. Nucleic Acids Res. 21:1993;4411-4412.
61. Rivera V. M., Clackson T., Natesan S., Pollock R., Amara J. F., Keenan T., Magari S. R., Phillips T., Courage N. L., Cerasoli F. J., Holt D. A., Gilman M. A humanized system for pharmacologic control of gene expression. Nat. Med. 2:1996;1028-1032.
62. Lu B., Federoff H. J. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum. Gene Ther. 6:1995;419-428.
63. Miyatake S., Iyer A., Martuza R. L., Rabkin S. D. Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71:1997;5124-5132.
64. Freundlieb S., Schirra-Muller C., Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J. Gene Med. 1:1999;4-12.
65. Pechan P. A., Fotaki M., Thompson R. L., Dunn R., Chase M., Chiocca E. A., Breakefield X. O. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum. Gene Ther. 7:1996;2003-2013.